Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 3Endocrine 3Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Stomach Neoplasms 1Sarcoma 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Magnetic Resonance Spectroscopy 7gallium Ga 68 dotatate 6lutetium Lu 177 dotatate 4Fluorodeoxyglucose F18 33-Iodobenzylguanidine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3fluorodopa F 18 2Specimen Handling 2FAPI-46 2Everolimus 2Erlotinib Hydrochloride 2vandetanib 1romidepsin 1pertuzumab 1pentetreotide 1olaparib 1fludarabine phosphate 1entrectinib 1dactolisib 1cabozantinib 1atezolizumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Whole Body Imaging 1Tretinoin 1Respiratory Therapy 1Quality of Life 1Positron-Emission Tomography 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × PM 01183 × CNS × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡